Bausch Health Companies (NYSE:BHC) had its target price increased by Royal Bank of Canada from $30.00 to $31.00 in a report released on Wednesday. Royal Bank of Canada currently has a hold rating on the stock.

A number of other brokerages have also weighed in on BHC. Zacks Investment Research upgraded Bausch Health Companies from a hold rating to a buy rating and set a $31.00 price objective for the company in a research note on Wednesday, October 3rd. ValuEngine lowered Bausch Health Companies from a hold rating to a sell rating in a research note on Tuesday, October 2nd. Mizuho restated a buy rating and set a $35.00 price objective on shares of Bausch Health Companies in a research note on Monday, October 8th. HC Wainwright set a $25.00 price objective on Bausch Health Companies and gave the company a hold rating in a research note on Monday, October 8th. Finally, Morgan Stanley upgraded Bausch Health Companies from an equal weight rating to an overweight rating and set a $32.00 price objective for the company in a research note on Monday, November 5th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the stock. Bausch Health Companies presently has a consensus rating of Hold and an average target price of $27.55.

NYSE BHC traded down $0.09 during mid-day trading on Wednesday, reaching $27.20. 3,898,414 shares of the company’s stock traded hands, compared to its average volume of 4,904,969. Bausch Health Companies has a 1-year low of $13.86 and a 1-year high of $28.45. The company has a quick ratio of 0.89, a current ratio of 1.14 and a debt-to-equity ratio of 7.55. The firm has a market cap of $9.48 billion, a PE ratio of 7.10, a price-to-earnings-growth ratio of 0.37 and a beta of -0.28.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Tuesday, November 6th. The company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.31. Bausch Health Companies had a positive return on equity of 32.19% and a negative net margin of 40.41%. The firm had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.09 billion. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, analysts anticipate that Bausch Health Companies will post 3.7 earnings per share for the current year.

In other news, CFO Paul Herendeen bought 10,000 shares of the firm’s stock in a transaction dated Friday, September 14th. The stock was bought at an average price of $22.61 per share, for a total transaction of $226,100.00. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Joseph C. Papa bought 30,000 shares of the firm’s stock in a transaction dated Friday, September 14th. The stock was purchased at an average price of $22.32 per share, with a total value of $669,600.00. The disclosure for this purchase can be found here. In the last quarter, insiders bought 165,000 shares of company stock valued at $3,890,700. Insiders own 11.54% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. NEXT Financial Group Inc acquired a new position in shares of Bausch Health Companies in the 3rd quarter worth approximately $101,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Bausch Health Companies in the 3rd quarter worth approximately $106,000. Polaris Greystone Financial Group LLC bought a new stake in shares of Bausch Health Companies in the 3rd quarter worth approximately $107,000. Quadrant Capital Group LLC bought a new stake in shares of Bausch Health Companies in the 3rd quarter worth approximately $118,000. Finally, Bedel Financial Consulting Inc. bought a new stake in shares of Bausch Health Companies in the 3rd quarter worth approximately $129,000. Institutional investors own 42.90% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

Further Reading: Insider Trading – What You Need to Know

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.